Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02100943 · ClinicalTrials.gov registry record
Exhaled NO as a Biomarker of Gestational OSA and Persistence Postpartum
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 76
- Enrollment target
NCT02100943: Completed study, sponsored by Wake Forest University Health Sciences.
NCT02100943 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 76 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02100943 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 76 participants
- Enrollment target
Study Summary
This study will evaluate the presence or absence of Obstructive Sleep Apnea (OSA) in the third trimester of pregnancy and again postpartum.
Primary Outcome
The difference in incidence of OSA during the third trimester and postpartum. We assumed an incidence of 25% during the third trimester, reducing to 6% postpartum. Comparison will be made with McNemar's test on proportions at an α level of 0.05.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-11-14 |
What the finished NCT02100943 record still lists
NCT02100943 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 76 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02100943 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02100943 about?
NCT02100943 is a clinical study titled "Exhaled NO as a Biomarker of Gestational OSA and Persistence Postpartum". This study will evaluate the presence or absence of Obstructive Sleep Apnea (OSA) in the third trimester of pregnancy and again postpartum.
What is the current status of trial NCT02100943?
This trial is currently completed. The enrollment target is 76 participants. The study started on 2014-03. Estimated completion is 2016-11-14.
Who is sponsoring clinical trial NCT02100943?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia